Prospective Multi-center Single-arm Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

  • End date
    Aug 11, 2023
  • participants needed
  • sponsor
    Medtronic - MITG
Updated on 11 February 2021


The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription.

A minimum of 10 centers in the United States, that have been trained on the use of the Carpediem system, will be invited to participate in the study. After obtaining institutional review board approval and written informed consent from a parent or legally authorized representative (LAR), data from all subjects treated with the Carpediem system will be included in the study. A minimum of 35 subjects will be enrolled and sites may be asked to screen and enroll patients for the study for up to 36 months.

Status of subjects discharged from hospital will be collected at 30- and-90 days following hospital discharge by phone interviews in accordance to local standard of care practices, review of in-hospital records or in-clinic visit, as available.


The post market surveillance study is designed to capture data in the real-world clinical setting on the use of the Carpediem system and will evaluate the safety and performance in children requiring CRRT in the US. Data on survival and the effectiveness of the Carpediem system on renal function recovery will be evaluated. A comprehensive evaluation of subjects being treated with Carpediem will include, but is not limited to, acuity at hospital/ICU admission and prior to CRRT initiation, Carpediem treatment parameters, laboratory data, and requirement for mechanical ventilation and/or inotropic support. Subject status and requirement for renal replacement therapy post hospital discharge will be evaluated at 30- and 90-days.

Condition Renal Failure, Acute renal failure, Fluid Overload, Volume Overload, Kidney Failure (Pediatric), Kidney Failure, hypervolemia, hyperhydration, acute kidney injury, acute kidney injuries
Treatment Carpediem System
Clinical Study IdentifierNCT04608149
SponsorMedtronic - MITG
Last Modified on11 February 2021


Yes No Not Sure

Inclusion Criteria

Parent or LAR has signed information consent
Subject weighs between 2.5-10 kg (or 5.5-22 lbs)
Subject is receiving medical care in an intensive care unit
Parental or LAR consent to receive full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours
Subject has a clinical diagnosis of acute kidney injury per Kidney Disease Improving Global Outcomes (KDIGO) criteria or fluid overload requiring CRRT

Exclusion Criteria

Subject is not expected to survive 72 hours due to an irreversible medical condition, in the opinion of the investigator
Subject has irreversible brain damage, in the opinion of the investigator
Subject is intolerant to anticoagulation, as documented in the medical record
Subject has a Do Not Attempt Resuscitate (DNAR), Allow Natural Death (AND), withdrawal of care or similar order, or anticipated change in status, in the opinion of the investigator, within the next 7 days
Subject has pre-existing end-stage renal disease or pre-existing, advanced chronic kidney disease, defined as an estimated Glomerular Filtration Rate (eGRF) < 30 ml/min/1.73m2
Subject has received at least 12 hours of CRRT with another machine (not including ECMO) during the current hospitalization
Subject is currently or has chronically been treated with a circulatory support device (i.e., left ventricular assist device (LVAD)) other than ECMO
Subject has had prior CRRT treatments using the Carpediem system
Subject is enrolled in clinical trials or being treated with other investigational therapeutic devices or products for acute kidney injury or fluid overload
Subject has any other medical condition that may confound the study objectives, in the opinion of the investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note